Contrasting effect of recombinant human erythropoietin on breast cancer cell response to cisplatin induced cytotoxicity

Sytkowski JA. Erythropoietin: Blood, Brain and Beyond. Boston: Wiley-VCH; 2004.10.1002/3527602380Search in Google Scholar

Jelkmann W, Wagner K. Beneficial and ominous aspects of the pleiotropic action of erythropoietin. Ann Hematol 2004; 83: 673-86.10.1007/s00277-004-0911-6Search in Google Scholar

Debeljak N, Sytkowski AJ. Erythropoietin: new approaches to improved molecular designs and therapeutic alternatives. Curr Pharm Des 2008; 14: 1302-10.10.2174/138161208799316393Search in Google Scholar

Lacombe C, Mayeux P. The molecular biology of erythropoietin. Nephrol Dial Transplant 1999; 14: 22-8.10.1093/ndt/14.suppl_2.22Search in Google Scholar

Sytkowski AJ. The neurobiology of erythropoietin. Cell Mol Neurobiol 2011; 31: 931-7.10.1007/s10571-011-9695-0Search in Google Scholar

Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ. The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hemat 2008; 67: 39-61.10.1016/j.critrevonc.2008.03.006Search in Google Scholar

Debeljak N, Sytkowski AJ. EpoR. UCSD-Nature Molecule Pages 2007. (doi: 10.1038/mp.a000863.01)Search in Google Scholar

Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol 2008; 141: 14-31.10.1111/j.1365-2141.2008.07014.xSearch in Google Scholar

Vaupel P, Thews O, Hoeckel M. Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol 2001; 18: 243-59.10.1385/MO:18:4:243Search in Google Scholar

Chang J, Couture F, Young S, McWatters KL, Lau CY. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 2005; 23: 2597-605.10.1200/JCO.2004.12.027Search in Google Scholar

Velenik V, Oblak I, Kodre V. Managing anemia with epoetin alfa in patients with rectal cancer. Radiol Oncol 2005; 39: 133-40.Search in Google Scholar

Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362: 1255-60.10.1016/S0140-6736(03)14567-9Search in Google Scholar

Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003; 4: 459-60.10.1016/S1470-2045(03)01163-XSearch in Google Scholar

Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005; 23: 5960-72.10.1200/JCO.2005.06.150Search in Google Scholar

Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009; 373: 1532-42.10.1016/S0140-6736(09)60502-XSearch in Google Scholar

Glaspy J, Crawford J, Vansteenkiste J, Henry D, Rao S, Bowers P, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010; 102: 301-15.10.1038/sj.bjc.6605498281666220051958Search in Google Scholar

Ludwig H, Crawford J, Osterborg A, Vansteenkiste J, Henry DH, Fleishman A, et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol 2009; 27: 2838-47.10.1200/JCO.2008.19.113019380447Search in Google Scholar

Tonelli M, Hemmelgarn B, Reiman T, Manns B, Reaume MN, Lloyd A, et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ 2009; 180: E62-71.10.1503/cmaj.090470268321019407261Search in Google Scholar

Sytkowski AJ. Does erythropoietin have a dark side? Epo signaling and cancer cells. Sci STKE 2007; 2007: pe38.10.1126/stke.3952007pe3817636183Search in Google Scholar

Fodor J, Major T, Tóth J, Sulyok Z, Polgár C. Comparison of mastectomy with breast-conserving surgery in invasive lobular carcinoma: 15-Year results. Rep Pract Oncol Radiother. 2011; 16: 227-31.10.1016/j.rpor.2011.06.005386321524376985Search in Google Scholar

Lekic M, Kovac V, Triller N, Knez L, Sadikov A, Cufer1 T. Outcome of small cell lung cancer (SCLC) patients with brain metastases in a routine clinical setting. Radiol Oncol 2012; 46(3): 213-225.; 46: 54-9.10.2478/v10019-012-0007-1342376622933980Search in Google Scholar

Małecki K, Gliński B, Mucha-Małecka A, Ryś J, Kruczak A, Roszkowski K, et al. Prognostic and predictive significance of p53, EGFr, Ki-67 in larynx preservation treatment. Rep Pract Oncol Radiother. 2010; 15: 87-92.10.1016/j.rpor.2010.06.001386320224376930Search in Google Scholar

Kovač V, Smrdel U. Meta-analyses of clinical trials in patients with non-small cell lung cancer. Neoplasma 2004; 51: 334-40.Search in Google Scholar

Martin M. Platinum compounds in the treatment of advanced breast cancer. Clin Breast Cancer 2001; 2: 190-208.10.3816/CBC.2001.n.02211899413Search in Google Scholar

Todorovic V, Sersa G, Flisar K, Cemazar M. Enhanced cytotoxicity of bleomycin and cisplatin after electroporation in murine colorectal carcinoma cells. Radiol Oncol 2009; 43: 264-73.10.2478/v10019-009-0037-5Search in Google Scholar

Erčulj N, Kovač V, Hmeljak J, Dolžan V. The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma. Ann Oncol 2012; 23: 961-7.10.1093/annonc/mdr32421765044Search in Google Scholar

Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22: 7265-79.10.1038/sj.onc.120693314576837Search in Google Scholar

Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001; 61: 3561-5.Search in Google Scholar

Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 2005; 23: 7721-35.10.1200/JCO.2005.09.00416234531Search in Google Scholar

Larsson AM, Jirstrom K, Fredlund E, Nilsson S, Ryden L, Landberg G, et al. Erythropoietin receptor expression and correlation to tamoxifen response and prognosis in breast cancer. Clin Cancer Res 2009; 15: 5552-9.10.1158/1078-0432.CCR-08-301419706814Search in Google Scholar

Belenkov AI, Shenouda G, Rizhevskaya E, Cournoyer D, Belzile JP, Souhami L, et al. Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin. Mol Cancer Ther 2004; 3: 1525-32.10.1158/1535-7163.1525.3.12Search in Google Scholar

Kumar SM, Zhang G, Bastian BC, Arcasoy MO, Karande P, Pushparajan A, et al. Erythropoietin receptor contributes to melanoma cell survival in vivo. Oncogene 2011.10.1038/onc.2011.366344183121860424Search in Google Scholar

Li J, Vesey DA, Johnson DW, Gobe G. Erythropoietin reduces cisplatin-induced apoptosis in renal carcinoma cells via a PKC dependent pathway. Cancer Biol Ther 2007; 6: 1944-50.10.4161/cbt.6.12.497518075299Search in Google Scholar

Palumbo C, Battisti S, Carbone D, Albonici L, Alimandi M, Bei R, et al. Recombinant erythropoietin differently af fects proliferation of mesothelioma cells but not sensitivity to cisplatin and pemetrexed. Cancer Chemother Pharmacol 2008; 61: 893-901.10.1007/s00280-007-0608-317922127Search in Google Scholar

Shi Z, Hodges VM, Dunlop EA, Percy MJ, Maxwell AP, El-Tanani M, et al. Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line. Molecular cancer research : MCR 2010; 8: 615-26.10.1158/1541-7786.MCR-09-026420353997Search in Google Scholar

Hayakawa J, Ohmichi M, Kurachi H, Kanda Y, Hisamoto K, Nishio Y, et al. Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res 2000; 60: 5988-94.Search in Google Scholar

Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: RESEARCH0034.10.1186/gb-2002-3-7-research0034Search in Google Scholar

Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009; 55: 611-22.10.1373/clinchem.2008.112797Search in Google Scholar

Kutuk O, Arisan ED, Tezil T, Shoshan MC, Basaga H. Cisplatin overcomes Bcl-2-mediated resistance to apoptosis via preferential engagement of Bak: critical role of Noxa-mediated lipid peroxidation. Carcinogenesis 2009; 30: 1517-27.10.1093/carcin/bgp165Search in Google Scholar

Abramoff MD, Magelhaes PJ, Ram SJ. Image Processing with ImageJ. Biophotonics International 2004; 11: 36-42.Search in Google Scholar

Smyth GK. Limma: linear models for microarray data. In: Robert Gentleman VJC, Wolfgang Huber, Rafael A. Irizarry, Sandrine Dudoit editor. Bioinformatics and Computational Biology Solutions Using R and Bioconductor. New York: Springer; 2005. p. 397-420.10.1007/0-387-29362-0_23Search in Google Scholar

(2008) RDCT. R: A language and environment for statistical computing. Vienna: R Fundation for Statistical Computing; 2011.Search in Google Scholar

Benjamini Y, Hochberg Y. Controlling the False Discovery Rate - a Practical and Powerful Approach to Multiple Testing. R Stat Soc Series B Stat Methodol 1995; 57: 289-300.10.1111/j.2517-6161.1995.tb02031.xSearch in Google Scholar

Zager V, Cemazar M, Hreljac I, Lah TT, Sersa G, Filipic M. Development of human cell biosensor system for genotoxicity detection based on DNA damage-induced gene expression. Radiol Oncol 2010; 44: 42-51.10.2478/v10019-010-0010-3Search in Google Scholar

Henkels KM, Turchi JJ. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines. Cancer Res 1999; 59: 3077-83.Search in Google Scholar

Yamashita H, Nevalainen MT, Xu J, LeBaron MJ, Wagner KU, Erwin RA, et al. Role of serine phosphorylation of Stat5a in prolactin-stimulated beta-casein gene expression. Mol Cell Endocrinol 2001; 183: 151-63.10.1016/S0303-7207(01)00546-9Search in Google Scholar

Lu CH, Shen Q, DuPre E, Kim H, Hilsenbeck S, Brown PH. cFos is critical for MCF-7 breast cancer cell growth. Oncogene 2005; 24: 6516-24.10.1038/sj.onc.1208905Search in Google Scholar

Perkins ND. Achieving transcriptional specificity with NF-kappa B. Int J Biochem Cell B 1997; 29: 1433-48.10.1016/S1357-2725(97)00088-5Search in Google Scholar

Patel HR, Sytkowski AJ. Erythropoietin activation of AP1 (Fos/Jun). Exp Hematol 1995; 23: 619-25.Search in Google Scholar

Mariggio S, Bavec A, Natale E, Zizza P, Salmona M, Corda D, et al. Galpha13 mediates activation of the cytosolic phospholipase A2alpha through fine regulation of ERK phosphorylation. Cellular signalling 2006; 18: 2200-8.10.1016/j.cellsig.2006.05.00316806823Search in Google Scholar

Schnellmann RG, Zhuang SG. A death-promoting role for extracellular signal-regulated kinase. J Pharmacol Exp Ther 2006; 319: 991-7.10.1124/jpet.106.10736716801453Search in Google Scholar

Marone R, Cmiljanovic V, Giese B, Wymann MP. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta 2008; 1784: 159-85.10.1016/j.bbapap.2007.10.00317997386Search in Google Scholar

Gewirtz DA, Di X, Walker TD, Sawyer ST. Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs. Clin Cancer Res 2006; 12: 2232-8.10.1158/1078-0432.CCR-05-228716609039Search in Google Scholar

Sigounas G, Sallah S, Sigounas VY. Erythropoietin modulates the anticancer activity of chemotherapeutic drugs in a murine lung cancer model. Cancer Lett 2004; 214: 171-9.10.1016/j.canlet.2004.06.00915363543Search in Google Scholar

Zhang L, Yu J. PUMA, a potent killer with or without p53. Oncogene 2008; 27: S71-S83.10.1038/onc.2009.45286043219641508Search in Google Scholar

Pelekanou V, Kampa M, Kafousi M, Dambaki K, Darivianaki K, Vrekoussis T, et al. Erythropoietin and its receptor in breast cancer: correlation with steroid receptors and outcome. Cancer Epidemiol Biomarkers Prev 2007; 16: 2016-23.10.1158/1055-9965.EPI-06-102317932349Search in Google Scholar

Pelekanou V, Notas G, Sanidas E, Tsapis A, Castanas E, Kampa M. Testosterone membrane-initiated action in breast cancer cells: Interaction with the androgen signaling pathway and EPOR. Molec Oncol 2010; 4: 135-49.10.1016/j.molonc.2010.01.004552789220189893Search in Google Scholar

Notas G, Kampa M, Pelekanou V, Castanas E. Interplay of estrogen receptors and GPR30 for the regulation of early membrane initiated transcriptional effects: A pharmacological approach. Steroids 2011.10.1016/j.steroids.2011.11.00522138208Search in Google Scholar